Related Experiment Video
Updated: Jan 13, 2026

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
Published on: October 25, 2024
Lefamulin or moxifloxacin for community-acquired pneumonia: balancing innovation, safety, and evidence
Saad Arsalan Wasti1, Areesha Wasti2, Muhammad Usman Iqbal1
1Department of Medicine, King Edward Medical University, Lahore, Pakistan.
Abstract:
The recent approval of lefamulin presents an alternative to fluoroquinolones for community-acquired pneumonia. In recent trials, lefamulin matched moxifloxacin in early clinical response and safety, with a favorable activity spectrum including atypical pathogens. However, fluoroquinolones remain entrenched due to cost, clinician familiarity, and broad guidelines. This letter examines current evidence comparing the two, highlights potential niches for lefamulin, and calls for more trials to guide adoption in diverse healthcare settings.
More Related Videos
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
03:22Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
Published on: March 1, 2024
Related Concept Videos
Antimicrobial Effectiveness
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Antibiotic Selection
Development of Antibiotic Resistance
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence